{"id":"meropenem-vaborbactam","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Seizures"}]},"_chembl":{"chemblId":"CHEMBL127","moleculeType":"Small molecule","molecularWeight":"383.47"},"_dailymed":{"setId":"e237fd0f-3050-42a3-b43e-b6fb4824e93d","title":"VABOMERE (MEROPENEM-VABORBACTAM) INJECTION, POWDER, FOR SOLUTION [MELINTA THERAPEUTICS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meropenem is a broad-spectrum carbapenem that binds to penicillin-binding proteins and disrupts bacterial cell wall synthesis. Vaborbactam is a cyclic boronic acid beta-lactamase inhibitor that protects meropenem from degradation by serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and carbapenem-resistant Enterobacteriaceae (CRE) enzymes, thereby restoring meropenem's activity against resistant gram-negative bacteria.","oneSentence":"Meropenem-vaborbactam is a carbapenem antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the carbapenem from enzymatic degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:57.691Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria"},{"name":"Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible gram-negative bacteria"}]},"trialDetails":[{"nctId":"NCT06828848","phase":"PHASE2","title":"A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections","status":"RECRUITING","sponsor":"Menarini Group","startDate":"2025-02-18","conditions":"Gram Negative Infections","enrollment":44},{"nctId":"NCT06672978","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis","status":"RECRUITING","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)","startDate":"2025-06-03","conditions":"Acute Pyelonephritis, Complicated Urinary Tract Infection","enrollment":66},{"nctId":"NCT07160569","phase":"","title":"Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-09-01","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":100},{"nctId":"NCT02687906","phase":"PHASE1","title":"Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)","startDate":"2016-07","conditions":"Bacterial Infections","enrollment":39},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT05566665","phase":"","title":"Nosocomial Infections in ECMO Patients","status":"RECRUITING","sponsor":"Policlinico Hospital","startDate":"2023-01-01","conditions":"Acute Respiratory Distress Syndrome, Nosocomial Infection, Extracorporeal Membrane Oxygenation Complication","enrollment":200},{"nctId":"NCT05048693","phase":"","title":"Use of New Antibiotics in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-11-01","conditions":"Multi-antibiotic Resistance","enrollment":41},{"nctId":"NCT02168946","phase":"PHASE3","title":"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults","status":"COMPLETED","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)","startDate":"2014-07","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia","enrollment":77},{"nctId":"NCT03006679","phase":"PHASE3","title":"A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia","status":"WITHDRAWN","sponsor":"Melinta Therapeutics, Inc.","startDate":"2018-08","conditions":"Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, Hospital-Acquired Pneumonia","enrollment":""},{"nctId":"NCT03564158","phase":"PHASE1","title":"Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers","status":"COMPLETED","sponsor":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)","startDate":"2018-05-01","conditions":"Healthy","enrollment":53},{"nctId":"NCT02166476","phase":"PHASE3","title":"Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2014-11-20","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis","enrollment":550},{"nctId":"NCT02020434","phase":"PHASE1","title":"The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency","status":"COMPLETED","sponsor":"Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)","startDate":"2014-01","conditions":"Subjects With Varying Degrees of Renal Insufficiency and, Subjects With Normal Renal Function","enrollment":32},{"nctId":"NCT02073812","phase":"PHASE1","title":"Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)","startDate":"2014-02","conditions":"Healthy Subjects","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":522,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vabomere","Combination vaborbactam and meropenem","beta-lactamase inhibitor and carbapenem antibiotic","Carbavance","Meropenem 2 g-Vaborbactam 2 g"],"phase":"marketed","status":"active","brandName":"Meropenem-Vaborbactam","genericName":"Meropenem-Vaborbactam","companyName":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)","companyId":"rempex-a-wholly-owned-subsidiary-of-melinta-therapeutics-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Meropenem-vaborbactam is a carbapenem antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the carbapenem from enzymatic degradation. Used for Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria, Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible gram-negative bacteria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}